News

Mr Mulder replaces Jake Philip, who has resigned his positions as CEO and director of the company to pursue other interests. Previously, Mr Mulder served for two years

Sepracor determined that the study did not meet its primary efficacy endpoint, which was reduction in symptoms of generalized anxiety disorder, as assessed using the clinician-rated Hamilton anxiety

Oxygen Biotherapeutics, a developer of biotechnology products, and Virginia Commonwealth University have signed a memorandum of understanding to establish a federal defense appropriation-funded joint venture focusing on developing

According to Nomir Medical, preliminary analysis of the data demonstrates that after Noveon treatment, 76.3% of the toes showed evidence of improvement, and a significant drop in positive

Effective April 1, 2009, Kazuya Obe will return to Sysmex Corporate after a six-year tenure in the US and serve in an international business leadership position. He will

Mr Chiminski will also serve as a member of the board of directors of Catalent. George Fotiades, who has been serving as president and CEO on an interim

Prior to joining Abiomed, Mr Howley spent 20 years at GE Healthcare. From 2006 to 2009, he was general manager at GE Healthcare, overseeing the Americas X-ray and

Endo Pharmaceuticals, a specialty pharmaceutical company, has given notice that it is returning to Durect, a specialty pharmaceutical company, its rights in the US and Canada to develop

The company will split its US sales operations into three market segments: neurology, neurointerventional, and physician office. The neurology market includes neurologists and physical medicine and rehabilitation physicians.